OOIR: Observatory of International Research

Papers

(The TQCC of Trends in Cancer is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Dying to survive: harnessing inflammatory cell death for better immunotherapy	268
Advisory Board and Contents	201
Subscription & copyright page	161
Cancer evolution: from Darwin to the Extended Evolutionary Synthesis	153
Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology	147
The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatments	137
Subscription & copyright page	130
On the path to equity in cancer research and care	127
Subscription & copyright page	124
Challenges and opportunities for physician-scientists in advancing cancer research	117
Subscription and copyright page	114
Subscription & copyright page	109
Ancestry-defined molecular taxonomy of prostate cancer	107
Many faces, many places: delving deeper into CAF heterogeneity in NSCLC	103
Subscription & copyright page	102
Advisory Board and Contents	98
Quantifying Cancer: More Than Just a Numbers Game	97
Subscription &copyright page	97
Subscription & copyright page	94
State-matched organoid models to fight pancreatic cancer	94
Subscription & copyright page	93
Integrating Quantitative Approaches in Cancer Research and Oncology	93
Advisory Board and Contents	91
Interferon signaling restrains renal cell carcinoma heterogeneity	87
Advisory Board and Contents	85

Revumenib: a new era in acute leukemia treatment	82
Pearls and pitfalls of ChatGPT in medical oncology	80
Advisory Board and Contents	80
Advisory Board and Contents	77
Space in cancer biology: its role and implications	74
Matrix stiffness primes cells for future oxidative stress	73
FBXW10: a male-biased E3 ligase in liver cancer	72
Ferroptosis vulnerability in FLT3-mutant leukemia	71
‘Slicing’ glioblastoma drivers with the Swiss cheese model	64
Endogenous retroelements as alarms for disruptions to cellular homeostasis	62
Bacteria-derived L-lactate fuels cervical cancer chemoradiotherapy resistance	61
Engineered bacterial therapeutics for detecting and treating CRC	60
Label-free optical imaging for brain cancer assessment	59
Targeting TEAD-ious resistance	58
Engineering growth factor ligands and receptors for therapeutic innovation	58
Solving the puzzle of what makes immunotherapies work	57
Concepts and Applications of Information Theory to Immuno-Oncology	57
Connecting Timescales in Biology: Can Early Dynamical Measurements Predict Long-Term Outcomes?	54
Impact of tissue-agnostic approvals for patients with gastrointestinal malignancies	54
Impact of tissue-agnostic approvals on management of primary brain tumors	53
Targeting the Mevalonate Pathway in Cancer	53
Into the era of mycobiome-driven cancer research	53
A Quantitative Paradigm for Decision-Making in Precision Oncology	52
Epigenetic underpinnings of tumor-immune dynamics in prostate cancer immune suppression	51
Serrated colorectal cancer: preclinical models and molecular pathways	50
Protease regulation of tumor-immune cell symbiosis	50
Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands	49
Adverse effects of ferroptotic therapy: mechanisms and management	49
Tumor mutational burden and immunotherapy in gliomas	49
Innate lymphoid cells: potential targets for cancer therapeutics	48
Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us	47
Myeloid cell path to malignancy: insights into liver cancer	47
Evolution of metastasis: new tools and insights	47
Clonal evolution and hierarchy in myeloid malignancies	46
Ferroptosis and Photodynamic Therapy Synergism: Enhancing Anticancer Treatment	46
Cancer cell adaptability: turning ribonucleoprotein granules into targets	46
Targeting synthetic lethal paralogs in cancer	45
Advances in targeting RNA modifications for anticancer therapy	44
Tumor-resident microbes: the new kids on the microenvironment block	44
Advances in LAG3 cancer immunotherapeutics	43
Integrating innate and adaptive immunity in oncolytic virus therapy	43
The peritumor microenvironment: physics and immunity	41
Epigenetic basis and targeting of cancer metastasis	40
Tumor-agnostic drug development in dMMR/MSI-H solid tumors	40
Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents	40
Necroptosis and tumor progression	38
Immunometabolism: A ‘Hot’ Switch for ‘Cold’ Pediatric Solid Tumors	38
Metastatic hormone-naïve prostate cancer: a distinct biological entity	38
How Comorbidities Shape Cancer Biology and Survival	38
IL-33 and ILC2 in pancreatic cancer: good, bad or a bit of both?	37

Next batter up! Targeting cancers with KRAS-G12D mutations	37
N of 1 Data Sharing: The Impact of Data Sharing within the Hematology–Oncology Drug Products Division of the US FDA	37
Subscription and copyright page	36
Advisory Board and Contents	36
Addressing the genetic/nongenetic duality in cancer with systems biology	36
Subscription and copyright page	35
Advisory Board and Contents	34
Next-generation cancer vaccines and emerging immunotherapy combinations	34
Apart, together	34
Subscription & copyright page	34
Subscription & copyright page	34
Advisory Board and Contents	33
Subscription & copyright page	33
Subscription and copyright page	33
Emerging metabolomic tools to study cancer metastasis	32
Thymic expression of immune checkpoint molecules and their implication for response to immunotherapies	32
CD4+ T cells help myeloid-mediated killing of immune-evasive tumors	31
Advisory Board and Contents	31
The development of therapy related myeloid neoplasms in childhood cancer survivors	31
Chemical-genetics refines transcription factor regulatory circuits	31
Advisory Board and Contents	31
Prognostic value of atypical B cells in breast cancer	30
Subscription & copyright page	30
Subscription & copyright page	30
Subscription & copyright page	30
Advisory Board and Contents	30
Epigenetic control of immunoevasion in cancer stem cells	29
Overstretched and overlooked: solving challenges faced by early-career investigators after the pandemic	29
NETscape or NEThance: tailoring anti-cancer therapy	29
Radiotherapy-induced metabolic hallmarks in the tumor microenvironment	28
Leveraging circulating microbial DNA for early cancer detection	28
Using Drosophila to uncover the role of organismal physiology and the tumor microenvironment in cancer	27
Subscription & copyright page	27
Next-generation immunotherapies for brain metastatic cancers	27
Biophysical determinants of cancer organotropism	27
Epigenetic reprogramming in pediatric gliomas: from molecular mechanisms to therapeutic implications	27
Aberrant nuclei with amplified DNA in cancer	27
In vivo macrophage engineering as novel therapeutic strategy against liver metastasis	27
COX2-dependent suppression of anticancer immunity	26
Subscription & copyright page	26
High-Fat Diet Impacts on Tumor Development in the Gut	26
Exercise against nonsmall-cell lung carcinoma: novel insights	26
Advisory Board and Contents	25
Mechanisms governing lineage plasticity and metabolic reprogramming in cancer	24
Immunomodulation by endothelial cells: prospects for cancer therapy	24
A new enhancer for anti-PD-1/PD-L1 immunotherapy: PCSK9 inhibition	24
Turning cold into hot: emerging strategies to fire up the tumor microenvironment	23
Advisory Board and Contents	22
Metabolic landscape of disseminated cancer dormancy	22
Engine shutdown: migrastatic strategies and prevention of metastases	22
Emerging roles of TBK1 in cancer immunobiology	22
Emerging roles of nucleotide metabolism in cancer	21
Immunogenicity of ferroptosis in cancer: a matter of context?	21
When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers	21
Antibody–drug conjugates: in search of partners of choice	20
Metabolic interplay: tumor macrophages and regulatory T cells	20
Accessing the vasculature in cancer: revising an old hallmark	20
Perivascular niches: critical hubs in cancer evolution	19
Drug independence and the curability of cancer by combination chemotherapy	19
Multifunctional role of thymidine phosphorylase in cancer	19
Radiotherapy and immunotherapy: open questions and future strategies	19
Role of financial toxicity in perpetuating health disparities	19
Cellular and molecular mechanisms of plasticity in cancer	19
Emerging signaling mediators in the anorexia–cachexia syndrome of cancer	19
TAZ/YAP fusion proteins: mechanistic insights and therapeutic opportunities	18
Resisting T cell attack: tumor-cell-intrinsic defense and reparation mechanisms	18
Immune organoids: from tumor modeling to precision oncology	18
Genitourinary cancer neoadjuvant therapies: current and future approaches	18
The conundrum of Helicobacter pylori-associated apoptosis in gastric cancer	18
Convergent insights into intratumor heterogeneity	18
Artificial intelligence-guided discovery of anticancer lead compounds from plants and associated microorganisms	18
Onco-condensates: formation, multi-component organization, and biological functions	18
Redrawing therapeutic boundaries: microbiota and cancer	18